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Erythropoietin treatment leads to reduced blood glucose levels
and body mass: Insights from murine models
Abstract
Erythropoietin (EPO) regulates proliferation and differentiation of erythroid precursor cells into
erythrocytes. The last decade has revealed non-renal sites of EPO production and extrahematopoietic
expression of the EPO-receptor (EPO-R), thus suggesting that EPO has pleiotropic functions. Here we
addressed the interplay between EPO / glucose metabolism / body weight, by employing a panel of
relevant experimental murine models. The models focused on situations of increased EPO levels,
including EPO injected C57BL/6 and BALB/c mice, as well as transgenic mice (tg6) constitutively
overexpressing human EPO, thus exposed to constantly high EPO serum levels. As experimental models
for diabetes and obesity, we employed protein Tyr phosphatase 1B (PTP1B) knockout mice associated
with resistance to diabetes (PTP1B-/-), and ob/ob mice susceptible to diabetes and obesity. The data
presented herein demonstrate EPO-mediated decrease in blood glucose levels in all mice models tested.
Moreover, in the ob/ob mice we observed EPO-mediated attenuation of body weight gain and reduction
of hemoglobin A1C. Taken together our data bear significant clinical implications of EPO treatment in
the management of a wide range of metabolic diseases, thus adding an important novel therapeutic
potential to this pleiotropic hormone.
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Erythropoietin (EPO) regulates proliferation and differentiation of erythroid precursor 42 
cells into erythrocytes. The last decade has revealed non-renal sites of EPO 43 
production and extrahematopoietic expression of the EPO-receptor (EPO-R), thus 44 
suggesting that EPO has pleiotropic functions. Here we addressed the interplay 45 
between EPO / glucose metabolism / body weight, by employing a panel of relevant 46 
experimental murine models. The models focused on situations of increased EPO 47 
levels, including EPO injected C57BL/6 and BALB/c mice, as well as transgenic mice 48 
(tg6) constitutively overexpressing human EPO, thus exposed to constantly high EPO 49 
serum levels. As experimental models for diabetes and obesity, we employed protein 50 
Tyr phosphatase 1B (PTP1B) knockout mice associated with resistance to diabetes 51 
(PTP1B-/-), and ob/ob mice susceptible to diabetes and obesity. The data presented 52 
herein demonstrate EPO-mediated decrease in blood glucose levels in all mice models 53 
tested. Moreover, in the ob/ob mice we observed EPO-mediated attenuation of body 54 
weight gain and reduction of hemoglobin A1C. Taken together our data bear 55 
significant clinical implications of EPO treatment in the management of a wide range 56 
of metabolic diseases, thus adding an important novel therapeutic potential to this 57 






The hematopoietic growth factor Erythropoietin (EPO) is produced in the kidney in 64 
response to hypoxia, and stimulates erythropoiesis in the bone marrow (Krantz 1991; 65 
Spivak, et al. 1991). Recombinant human EPO (rHuEPO) is an effective treatment for 66 
anemia of various etiologies, including anemias associated with renal failure 67 
(Eschbach, et al. 1989 ; Winearls, et al. 1986) and cancer-related (Mittelman 1996; 68 
Spivak 1994). The presence of EPO receptors (EPO-R) on cells other than erythroid 69 
progenitors, including endothelial, myocardial, neural and retinal cells, suggests that 70 
EPO has other biological functions in addition to erythropoiesis, reviewed in (Arcasoy 71 
2008). Hence, such functions include neuroprotection (Brines, et al. 2004; Cilloni, et 72 
al. 2004), anti-neoplastic activity (Katz, et al. 2005; Mittelman, et al. 2001), 73 
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improvement in congestive heart failure (Camici, et al. 2007; Fiordaliso, et al. 2005; 74 
Silverberg, et al. 2002). We (Ghezzi and Mengozzi 2007; Lifshitz, et al. 2009; 75 
Prutchi-Sagiv, et al. 2006a; Prutchi-Sagiv, et al. 2006b; Prutchi-Sagiv, et al. 2008), as 76 
well as others (Ghezzi and Mengozzi 2007), have found EPO associated improvement 77 
in immunological functions. 78 
 79 
In that respect, we have been attracted by the reports on EPO effects on glucose 80 
metabolism in haemodialysis patients (Allegra, et al. 1996; Borissova, et al. 1993),   81 
that are associated with elevated insulin sensitivity (Spaia, et al. 2000; Tuzcu, et al. 82 
2004). EPO effects were also documented on the metabolism of proteins and lipids; 83 
however, the latter are still controversial, reviewed in (Allegra, et al. 1997). 84 
 85 
The ability to control glucose, protein and lipid metabolism is of paramount value in 86 
clinical practice and is especially relevant in subjects with metabolic syndrome. 87 
Metabolic syndrome is common, affecting more than 30% of adults in the US 88 
(Feldeisen and Tucker 2007), and is referred to as a “cluster of metabolic 89 
abnormalities”, including obesity, hyperglycemia, dyslipidemia and hypertension 90 
(Chew, et al. 2006). In the 'modern' world, diet and lifestyle contribute to the high 91 
incidence of obesity which is linked to increased risk for diabetes, cancer and 92 
cardiovascular diseases, that leads to a reduction in life expectancy (Kolonin, et al. 93 
2004). In the last few decades the prevalence of obesity and diabetes has been 94 
increasing rapidly, reviewed in (Keller 2006). Consequently, the concern regarding 95 
obesity and its metabolic implications has directed intensive scientific effort 96 
concerning the adipose tissue, which is a major endocrine and signaling organ 97 
involved in a wide range of physiological responses, reviewed in (Rosen and 98 
Spiegelman 2006).  99 
 100 
The positive effect of rHuEPO treatment on glucose metabolism in hemodialyzed 101 
patients set the scene for exploring critically the interplay between EPO / glucose 102 
metabolism / body weight, in the absence of any clinical problems. We have thus 103 
employed a panel of relevant murine models to investigate this issue. The models 104 
focused on situations of increased EPO levels, including EPO injected C57BL/6 and 105 
BALB/c mice, as well as transgenic mice constitutively overexpressing human EPO 106 
in an oxygen independent manner (tg6; (Ruschitzka, et al. 2000; Vogel, et al. 2003)). 107 
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EPO plasma levels in these mice are typically 10-12 fold higher than wt EPO levels 108 
(under normoxic conditions) (Ruschitzka et al. 2000; Vogel et al. 2003). This 109 
elevation causes a doubling of their hematocrit from 40 to 80-90 % and up to 25% of 110 
the body weight is directed to the blood (Ruschitzka et al. 2000; Vogel et al. 2003). 111 
Expression of human EPO in these mice has been detected in the brain (where it most 112 
probably acts locally) as well as in the lung, from where it reaches circulation 113 
(Heinicke, et al. 2006). As experimental models for diabetes and obesity, we 114 
employed PTP1B knockout mice (Elchebly, et al. 1999) associated with resistance to 115 
diabetes (PTP1B-/-), and ob/ob mice susceptible to diabetes and obesity, reviewed 116 
(Houseknecht and Portocarrero 1998). Taken together, the data presented herein, 117 
demonstrate EPO-associated decrease in blood glucose levels and attenuation of body 118 
weight gain, thus bearing significant clinical implications in the management of a 119 
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Materials and methods 126 
 127 
Mice 128 
Female mice of the inbred strains BALB/c and C57BL/6, aged 8 and 12 weeks, 129 
respectively, were obtained from the Tel-Aviv University Animal Breeding Center. 130 
Transgenic mice overexpressing HuEPO (tg6; (Ruschitzka et al. 2000)) aged 3-6 131 
months were bred by us, and their wt littermates (C57BL/6) were used as controls. 132 
Male ob/ob mice [C57BL/6], aged 7 weeks, were obtained from Harlan (USA). Three 133 
month old male PTP1B-/- mice [BALB/c] were previously described (Elchebly et al. 134 
1999). Mice were maintained on a standard rodent chow diet (Koffolk, Israel). All 135 
procedures were approved by the animal care committees at the Sackler Faculty of 136 
Medicine Tel-Aviv University, Israel and at McGill University, Canada. 137 
 138 
Injected materials  139 
EPO - EPREX®, rHuEPO, Epoetin alfa (Cilag Ltd, Switzerland). Mice received three 140 
weekly injections (s.c.) of 180 U rHuEPO or diluent (control), for the duration of the 141 
experiment.  Glucose – D glucose (Sigma, USA). Insulin – Actrapid HM(ge) (Novo 142 
Nordisk, Israel).  143 
 144 
Food consumption 145 
Food consumption was measured during four weeks. Pre-weighed food was provided 146 
to the mice, the remaining food was measured subsequently, and the average food 147 
consumption per week was calculated for each mouse.   148 
 149 
Metabolic assays 150 
Serum glucose levels were determined by Accu-check go glucometer (Roche, 151 
Germany). Hemoglobin A1C (HbA1c) concentration in the blood was measured with 152 
DCA2000 analyzer (Bayer, USA). Serum insulin levels were measured using a 153 
commercial enzyme immunoassay kit (Mercodia, Sweden).  154 
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Glucose tolerance test (GTT) – mice deprived of food for over four hours received an 155 
intraperitoneal injection of glucose (2 g/kg body weight). Blood samples were then 156 
obtained from the tail for glucose determination at the indicated times.  157 
 158 
Statistical analysis 159 
Results are expressed as the mean ± standard error of the mean (SEM). All results 160 
were analyzed by Student's unpaired two-tailed t-test. Values of P < 0.05 were 161 
considered statistically significant.  162 
 163 
Page 6 of 28
joe@endocrinology.org
Manuscript submitted for review to Journal of Endocrinology
For Review Only
  Katz et al., Erythropoietin mediated reduction in blood glucose   
 7
Results 164 
We first examined, under non-fasting conditions, the effect of constitutively 165 
10-12 fold elevated EPO serum levels on blood glucose level EPO overexpressing 166 
transgenic mice (tg6) (Ruschitzka et al. 2000). As shown in Fig. 1A, tg6 mice are 167 
hypoglycemic as compared to their normal (wt) littermates. Hence, in the fed state, 168 
tg6 mice displayed 49% less glucose level in their blood compared to the wt. This 169 
finding raised the question of whether short exposure to EPO may also affect the 170 
blood glucose levels. We thus compared the effect of rHuEPO treatment on blood 171 
glucose levels in murine models that are associated with diabetes and obesity (Fig. 1B 172 
and C), as well as wt mice (Fig. 1D and E). In these experiments, mice were injected 173 
with rHuEPO (180U), three times weekly on alternating days. We found that after one 174 
week of treatment, all rHuEPO-treated mice had lower blood glucose levels, and these 175 
levels were further reduced during the second week of treatment. Moreover, this 176 
reduction was also observed within the group of rHuEPO-treated mice as compared to 177 
their initial blood glucose levels.  178 
To investigate the effect of EPO on glucose clearance, we performed a glucose 179 
tolerance test (GTT) in all mice (Fig. 2). In rHuEPO-treated mice the test was 180 
performed during the third week of treatment. Administration of a bolus of glucose to 181 
tg6 and rHuEPO-treated mice resulted in a more rapid clearance of glucose than was 182 
observed in wt and the control group receiving just the diluent, instead of rHuEPO. In 183 
tg6 mice, a prominent hypoglycemia was evident 15 min following the glucose 184 
injection.  185 
In order to determine whether tg6 mice are particularly sensitive to insulin, we 186 
measured serum insulin levels at fed state, and performed intraperitoneal insulin 187 
tolerance test (Fig. 3). The results show that tg6 mice have lower serum insulin levels 188 
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compared to their wt littermates (Fig. 3A). It thus appears that tg6 mice are more 189 
insulin sensitive, because they maintained lower glucose levels with significantly 190 
reduced insulin concentrations. This was further substantiated as based on the results 191 
of the insulin tolerance test. The results indicated a hypoglycemic response in tg6 192 
mice 15 min after insulin injection, a state that was evident at all time points. In 193 
contrast, wt mice had hyperglycemic response at 15 min, followed by a hypoglycemic 194 
response at the later time points (Fig. 3B).  195 
Based on these data, we assessed the ability of EPO to affect the glucose 196 
metabolism, using HbA1c measurements. This test was based on the fact that in 197 
patients with diabetes, HbA1c levels reflect the blood glucose levels during the 198 
preceding period of several months (Rohlfing, et al. 2002). We thus measured HbA1c 199 
in tg6 and rHuEPO-treated ob/ob mice (Fig. 4). Due to the rapid half life of 200 
circulating erythrocytes in mice, the test was performed in ob/ob mice during the third 201 
week of rHuEPO treatment. HbA1c was reduced by 18% and 15% in tg6 and 202 
rHuEPO-treated ob/ob mice, respectively, compared to their relevant control groups. 203 
Furthermore, the decrease in ob/ob mice was evident already after a short rHuEPO 204 
treatment.  205 
We next questioned whether EPO has any effect on the body mass. We 206 
measured the body weight of tg6 mice as compared to their wt littermates. As shown 207 
in Fig. 5A, the body weight of tg6 mice was lower than that of wt mice, in both males 208 
and females. To determine whether these weight differences result from a decrease in 209 
food intake, we estimated the amount of food consumed by the mice (Fig. 5B).  The 210 
results showed that food intake was actually higher in tg6 mice than in wt mice. 211 
Hence, tg6 mice maintained low body weight, even when higher amounts of food 212 
were consumed. To further resolve the differences in body weight we analyzed the 213 
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weights of distinct tissues, including liver, muscle (gastrocnemius), epididimal fat and 214 
spleen tissue (Fig. 6). Although histological examination of these organs revealed no 215 
overt differences, we found that tg6 mice had 42% less epididimal fat mass compared 216 
to their wt littermates. Differences in adipose tissues were also noted in the 217 
subcutaneous skin fat; tg6 mice had very thin skin with a thin layer of subcutaneous 218 
fat. However, the blood lipids profile of the tg6 mice did not differ from those of the 219 
wt littermates (data not shown).  220 
To evaluate the clinical significance of these EPO effects on the body mass, 221 
we examined whether rHuEPO treatment has any effect on the body mass in ob/ob 222 
mice. We thus measured the body weight gain and food consumption of ob/ob mice 223 
during two weeks of rHuEPO treatment (Fig. 7). The results indicated that rHuEPO- 224 
treated ob/ob mice gained less weight compared to the non-treated ob/ob mice. Hence, 225 
while non-treated ob/ob mice had 24% weight gain, the rHuEPO-treated ob/ob mice 226 
had only 17% weight gain (p<0.004), in spite of the fact that there was no difference 227 
in food intake between these groups.  228 
Taken together, our data indicate that EPO has effects on glucose homeostasis, 229 
insulin sensitivity and body mass, pointing to potential benefits to diabetic and obese 230 
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Discussion  237 
The present study deals with the emerging concept that EPO is a pleiotropic 238 
hormone, acting also beyond its role in erythropoiesis (Krantz 1991). Previous reports 239 
have documented an effect of EPO on reduction of blood glucose levels (Allegra et al. 240 
1996; Cayla, et al. 1999; Rasic-Milutinovic, et al. 2008). Most of these studies were 241 
performed on patients suffering from diabetes, a condition linked to insulin resistance 242 
(Pothiwala, et al. 2009). Long-term rHuEPO therapy was found to improve glucose 243 
metabolism in maintenance hemodialysis patients, mainly by reduction of insulin 244 
resistance (Allegra et al. 1996). In rats EPO treatment was also associated with lowered 245 
blood glucose levels, both in resting and under physical stress (Cayla et al. 1999).  246 
In the current study we explored the effect of EPO on glucose metabolism by 247 
employing a panel of murine experimental models. Each of these models enables a 248 
unique analysis of the in-vivo effects of EPO on blood glucose and/or body weight. We 249 
measured these parameters under constant exposure to high EPO levels, as well as 250 
under short term exposure to EPO (EPO-injected mice). The transgenic murine model 251 
tg6, that overexpresses human EPO (Ruschitzka et al. 2000) was thus employed to 252 
determine the effects of long term, constant exposure to high EPO levels. The EPO 253 
injected mice included (a) normal – wild type C57BL/6 and BALB/c mice; (b) PTP1B-/- 254 
mice that are resistant to both diabetes and obesity (Elchebly et al. 1999; Klaman, et al. 255 
2000); (c) ob/ob mice as a model for obesity and diabetes (Muzzin, et al. 1996; 256 
Pelleymounter, et al. 1995).  257 
The results showed that the tg6 mice that are continuously exposed to EPO were 258 
hypoglycemic, even under non-fasting conditions. This result gained support from the 259 
experiments in which EPO was administered to mice for a period of 2 weeks. 260 
Moreover, the effect of EPO on the reduction of glucose levels was evident already one 261 
week following EPO administration in all the experimental models tested, including the 262 
PTP1B-/-  and ob/ob mice. This conclusion gained further support by the metabolic tests, 263 
namely GTT. EPO overexpression or administration led to improved glucose clearance 264 
in all the tested murine models. Finally, HbA1c measurements provide a surrogate 265 
marker for blood glucose levels during several months prior to the test and are routinely 266 
employed clinically for the management of diabetes (Giugliano, et al. 2008; Rohlfing et 267 
al. 2002). In that respect, HbA1c levels were reduced in the rHuEpo treated ob/ob mice, 268 
thus pointing to the clinical relevance of EPO treatment to improve glucose metabolism 269 
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in diabetic subjects. The fact that the decrease in HbA1c was observed as early as three 270 
weeks following EPO administration, could result from the rapid metabolism 271 
characteristic of the mice (Wickler and Gleeson 1993), thereby differing from the 272 
profile of HbA1c response in human subjects (Bloomgarden 2006). Notably, the 273 
decrease in HbA1c in the tg6 mice was in the same range as in the EPO injected ob/ob 274 
mice, demonstrating that long term as well as short term exposures to EPO had a 275 
similar effect on this parameter, manifested in sustained levels of the HbA1c within the 276 
normal range.    277 
What could be the mechanisms of EPO effects on blood glucose levels? 278 
Lowered blood glucose associated with exposure to high EPO levels may result from 279 
an increase in the erythrocyte counts and their consequent uptake of glucose (Montel- 280 
Hagen, et al. 2009). At least two adaptive mechanisms allow the tg6 mice to cope 281 
with this excessive erythrocytosis: highly elevated NO expression as well as a reduced 282 
erythrocyte life span, the latter keeping the erythrocytes young and flexible and thus, 283 
preventing the blood from becoming too viscose (Bogdanova, et al. 2007; Ruschitzka 284 
et al. 2000; Vogel et al. 2003). Nevertheless, tg6 mice live only for about a year and 285 
die due to multiple organ degeneration (Heinicke et al. 2006). 286 
Analysis of the ventilatory response in hypoxia revealed that both cerebral and 287 
circulating EPO enhanced ventilation in hypoxic tg6 male and female mice (Soliz, et 288 
al. 2007; Soliz, et al. 2009). Interestingly, when measuring body temperature, oxygen 289 
consumption and carbon dioxide production under normoxia and hypoxia conditions 290 
neither of these parameters was changed compared to the wt control littermates, 291 
suggesting that the general metabolic drive was not changed. 292 
Another possibility to be considered, although not necessarily mutually exclusive is 293 
that EPO may also operate via increasing sensitivity to insulin. This is in line with our 294 
finding that the tg6 mice were more responsive to insulin and thus maintained lower 295 
glucose levels under lower levels of insulin, and insulin injection resulted actually in 296 
hypoglycemia (Fig. 3). EPO-associated increased sensitivity to insulin was not 297 
evident in the ob/ob mice treated with EPO for 2-3 weeks (data not shown). Hence, it 298 
is possible that longer exposure to EPO is necessary to mediate this effect in these 299 
mice. The findings that pancreatic beta-cells harbor functional EPO-Rs and that EPO 300 
acts directly on them (Fenjves, et al. 2003), raises the possibility that EPO treatment 301 
may also affect insulin secretion by the pancreatic cells.    302 
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The molecular mechanism by which EPO affects sensitivity to insulin is not yet 303 
resolved. EPO may operate via an increase in nitric oxide (NO) (Beleslin-Cokic, et al. 304 
2004), which is a powerful vasodilator as well as insulin-sensitizer, reviewed in 305 
(Marzo, et al. 2008). Of note tg6 mice express vast amounts of NO (Ruschitzka et al. 306 
2000). In addition, the transcription factor CEBP/α was found to decrease upon 307 
administration of EPO (Pinto, et al. 2008). This transcription factor was found to be 308 
associated with energy homeostasis (Hackett, et al. 1995). Thus for example, CEBP/α-/- 309 
mice do not display glycogen stores in the liver, they have elevated EPO-R mRNA in 310 
the liver and they die of hypoglycemia shortly following birth (Wang, et al. 1995; 311 
Zhang, et al. 1997). Our observation that liver CEBP/α levels are reduced in the tg6 312 
mice (data not shown) is in line with the possibility that the effects of EPO on glucose 313 
metabolism may also involve the reduction of this transcription factor.    314 
Our results in the murine models led us to an insight into possible clinical 315 
applications. In that respect, we examined the effect of EPO treatment on the glucose 316 
levels and insulin consumption in a diabetic patient. Indeed, EPO treatment reduced the 317 
blood glucose levels and reduced the required doses of insulin (data not shown). These 318 
data are supported by a recent report on the effects of EPO on lowered insulin 319 
consumption and HbA1c in a diabetic patient with chronic kidney disease-induced 320 
anemia (Brown, et al. 2009). These findings now call for an extensive clinical study, on 321 
a larger scale of patients. 322 
Concomitant with the effects of EPO on glucose levels and insulin sensitivity, we 323 
found that EPO administration or overexpression were associated with a decrease in 324 
body weight. This decrease is at least partially associated with reduced amount of fat 325 
tissue, especially evident in the leanness of the tg6 mice. Our results are in line with a 326 
recent publication demonstrating that targeted over expression of EPO in muscle tissue 327 
of mice protected against diet induced obesity and increased metabolic parameters 328 
(Hojman, et al. 2009). In line with this observation is our finding that EPO associated 329 
attenuated body weight gain in the ob/ob mice, despite the similar food intake as the 330 
diluent treated mice.  The precise mechanism underlying the decreased body weight has 331 
yet to be elucidated. It does not appear to be related to nausea with or without reduced 332 
food intake, since this parameter was tested and ruled out. An increased energy 333 
consumption or expenditure is thus a possible mechanism, related to the main findings 334 
of this study, i.e. reduced blood glucose levels associated with EPO.  335 
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To gain insight into the molecular mediators we questioned whether regulation of 336 
PTP1B could explain these EPO mediated effects on glucose metabolism. Our choice 337 
to focus on PTP1B leans on the finding that it is a pivotal down-regulator of insulin 338 
signaling (Boute, et al. 2003; Elchebly et al. 1999; Issad, et al. 2005; Rondinone, et al. 339 
2002; Waring, et al. 2003) and that PTP1B-/- mice are resistant to obesity and diabetes 340 
(Elchebly et al. 1999; Haj, et al. 2005; Klaman et al. 2000). Moreover, PTP1B was 341 
shown by us (Cohen, et al. 2004), and by others (Callero, et al. 2007), to participate in 342 
downregulation of EPO signaling. Our present finding that EPO treatment culminated 343 
in reduction of blood glucose in the PTP1B-/- mice, thus rules out the possibility that 344 
this EPO action is mediated via PTP1B.  345 
Various aspects of EPO action in rodent models have been documented, including 346 
prevention of diabetes-induced podocyte damage (Schiffer, et al. 2008), enhancement 347 
of wound healing (Galeano, et al. 2004) and promotion of vascular cell viability 348 
(Chong, et al. 2007). Taken together, our findings single out EPO as a potential novel 349 
glucose regulator. 350 
The current study exemplifies an exciting potential application for EPO as an 351 
adjunct anti-diabetic/obesity drug to reduce blood glucose levels and attenuate weight 352 
gain especially where these are associated with low levels of hemoglobin. Obviously, 353 
introducing EPO for these indications would require additional basic research as well as 354 
clinical trials. The idea that EPO acts on glucose metabolism places this hormone in a 355 
new and most important area, with significant clinical applications in diabetes and 356 
obesity. These are currently critical health issues at the forefront of medical and social 357 
interest. 358 
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 574 
Legends to Figures 575 
 576 
Figure 1: EPO-associated reduction in blood glucose levels  577 
(A). Blood glucose was measured in 3 months old tg6 mice and in their wt littermates. 578 
These measurements were under non-fasting conditions. (B-E) Murine models were 579 
injected with rHuEPO (180 U) or with diluent (control), 3 times weekly on alternating 580 
days, for a period of 2 weeks. Glucose measurements were performed before EPO 581 
injections (initial), and one and two weeks following EPO injections. These 582 
measurements were performed after 4 h of fasting. White and black squares represent 583 
diluent and EPO injected mice respectively. (B). ob/ob mice, 8 weeks old. (C). 584 
PTP1B-/- mice, 3 months old. (D). C57BL/6 mice, 3 months old. (E). BALB/c mice, 8 585 
weeks old. The number of mice in each group is indicated. Values depict mean ± 586 
SEM. *P < 0.02, **P < 0.003, *** P < 0.0001.  587 
Figure 2: Improved glucose tolerance conferred by EPO 588 
GTTs were performed in the following mouse strains: (A). tg6 and wt littermates 589 
(solid and open squares, respectively). (B). ob/ob. (C). PTP1B-/-. (D). C57BL/6. (E). 590 
BALB/c. For the rHuEPO and diluent treated mice, GTTs were performed after 2 591 
weeks of rHuEPO or diluent injections. The number of mice in each group is 592 
indicated, solid and open squares indicate EPO and diluent injected mice respectively. 593 
Values depict mean ± SEM. * P < 0.03, ** P < 0.003. 594 
Figure 3: Lower insulin levels (A) and increased sensitivity to insulin (B) in tg6 595 
mice 596 
(A). Serum concentrations of insulin in fed tg6 mice and their wt littermates, n = 5 597 
mice/group. *P = 0.04 (B) ITT was performed in tg6 mice and their wt littermates. 598 
Page 19 of 28
joe@endocrinology.org
Manuscript submitted for review to Journal of Endocrinology
For Review Only
  Katz et al., Erythropoietin mediated reduction in blood glucose   
 20
Blood glucose values are expressed as a percentage of glucose concentration, prior to 599 
insulin administration. n = 4 mice/group. Values depict mean ± SEM. *P = 0.05. 600 
Figure 4: EPO-associated reduction in hemoglobin A1c  601 
Groups of ob/ob mice were injected with rHuEPO or with diluent (control), three 602 
times weekly on alternating days for 3 weeks. Hemoglobin A1c was measured in the 603 
sera of the ob/ob mice (n = 5 and 6 for rHuEPO-treated and diluent-treated mice, 604 
respectively) and in the tg6 mice and their wt littermates (n = 4 and 3 tg6 and wt mice, 605 
respectively) using ELISA. Values depict mean ± SEM. *P < 0.03, **P = 0.001.  606 
Figure 5 : Reduced weight despite higher food consumption in tg6 mice 607 
Body weight and food consumption of tg6 mice (4 months old), as compared to their 608 
wt littermates. (A) Body weight of female tg6 mice and their wt littermates (n = 17 609 
(tg6) and 19 (wt) mice/group) and of male tg6 mice and their wt littermates (n = 8 610 
(tg6) and 6 (wt) mice/group), *P = 0.02, **P < 0.004. (B) Weekly food consumption 611 
of female and male tg6 mice and their wt littermates, as calculated over a period of 4 612 
weeks. Results are expressed as grams of food/mouse/week. n = 5 mice/group. Values 613 
depict mean weekly consumption of food per mouse ± SEM. **P < 0.004   614 
Figure 6: tg6 mice have less epididymal fat tissue 615 
 (A). Spleens, livers, muscle (gastrocnemius) and epididymal fat were dissected from 616 
female tg6 mice and their wt littermates and were weighed. Organ weights were 617 
normalized to total body weight. n = 3 mice/group, values depict mean ± SEM, *P = 618 
0.05, **P = 0.014. (B). Photographs of mouse cavities; the arrows indicate the 619 
epididymal fat. 620 
Figure 7: EPO administration attenuates weight gain in ob/ob mice  621 
Weight gain (A) and food consumption (B) of ob/ob mice injected with EPO or with 622 
diluent (control). Body weight is presented as percentage change from initial body 623 
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weight. Food consumption of individual ob/ob mice was measured for a period of 2 624 
weeks. Results are expressed as grams of food/mouse/week. n = 6 mice/group. Values 625 
depict mean ± SEM. * P = 0.03, ** P = 0.003. 626 
 627 
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Figure 1: EPO-associated reduction in blood glucose levels  
(A). Blood glucose was measured in 3 months old tg6 mice and in their wt littermates. These 
measurements were under non-fasting conditions. (B-E) Murine models were injected with rHuEPO 
(180 U) or with diluent (control), 3 times weekly on alternating days, for a period of 2 weeks. 
Glucose measurements were performed before EPO injections (initial), and one and two weeks 
following EPO injections. These measurements were performed after 4 h of fasting. White and black 
squares represent diluent and EPO injected mice respectively. (B). ob/ob mice, 8 weeks old. (C). 
PTP1B-/- mice, 3 months old. (D). C57BL/6 mice, 3 months old. (E). BALB/c mice, 8 weeks old. The 
number of mice in each group is indicated. Values depict mean ± SEM. *P < 0.02, **P < 0.003, *** 
P < 0.0001.  
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Figure 2: Improved glucose tolerance conferred by EPO 
GTTs were performed in the following mouse strains: (A). tg6 and wt littermates (solid and open 
squares, respectively). (B). ob/ob. (C). PTP1B-/-. (D). C57BL/6. (E). BALB/c. For the rHuEPO and 
diluent treated mice, GTTs were performed after 2 weeks of rHuEPO or diluent injections. The 
number of mice in each group is indicated, solid and open squares indicate EPO and diluent injected 
mice respectively. Values depict mean ± SEM. * P < 0.03, ** P < 0.003. 
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Figure 3: Lower insulin levels (A) and increased sensitivity to insulin (B) in tg6 mice 
(A). Serum concentrations of insulin in fed tg6 mice and their wt littermates, n = 5 mice/group. *P 
= 0.04 (B) ITT was performed in tg6 mice and their wt littermates. Blood glucose values are 
expressed as a percentage of glucose concentration, prior to insulin administration. n = 4 
mice/group. Values depict mean ± SEM. *P = 0.05. 
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Figure 4: EPO-associated reduction in hemoglobin A1c  
Groups of ob/ob mice were injected with rHuEPO or with diluent (control), three times weekly on 
alternating days for 3 weeks. Hemoglobin A1c was measured in the sera of the ob/ob mice (n = 5 
and 6 for rHuEPO-treated and diluent-treated mice, respectively) and in the tg6 mice and their wt 
littermates (n = 4 and 3 tg6 and wt mice, respectively) using ELISA. Values depict mean ± SEM. *P 
< 0.03, **P = 0.001.  
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Figure 5 : Reduced weight despite higher food consumption in tg6 mice 
Body weight and food consumption of tg6 mice (4 months old), as compared to their wt littermates. 
(A) Body weight of female tg6 mice and their wt littermates (n = 17 (tg6) and 19 (wt) mice/group) 
and of male tg6 mice and their wt littermates (n = 8 (tg6) and 6 (wt) mice/group), *P = 0.02, **P 
< 0.004. (B) Weekly food consumption of female and male tg6 mice and their wt littermates, as 
calculated over a period of 4 weeks. Results are expressed as grams of food/mouse/week. n = 5 
mice/group. Values depict mean weekly consumption of food per mouse ± SEM. **P < 0.004   
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Figure 6: tg6 mice have less epididymal fat tissue 
(A). Spleens, livers, muscle (gastrocnemius) and epididymal fat were dissected from female tg6 
mice and their wt littermates and were weighed. Organ weights were normalized to total body 
weight. n = 3 mice/group, values depict mean ± SEM, *P = 0.05, **P = 0.014. (B). Photographs of 
mouse cavities; the arrows indicate the epididymal fat. 
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Figure 7: EPO administration attenuates weight gain in ob/ob mice  
Weight gain (A) and food consumption (B) of ob/ob mice injected with EPO or with diluent (control). 
Body weight is presented as percentage change from initial body weight. Food consumption of 
individual ob/ob mice was measured for a period of 2 weeks. Results are expressed as grams of 
food/mouse/week. n = 6 mice/group. Values depict mean ± SEM. * P = 0.03, ** P = 0.003. 
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